208 related articles for article (PubMed ID: 33830023)
21. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507.
Koenecke C; Shaffer J; Alexander SI; Preffer F; Dombkowski D; Saidman SL; Dey B; McAfee S; Spitzer TR; Sykes M
Exp Hematol; 2003 Oct; 31(10):911-23. PubMed ID: 14550807
[TBL] [Abstract][Full Text] [Related]
22. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
23. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT.
Cichocki F; Cooley S; Davis Z; DeFor TE; Schlums H; Zhang B; Brunstein CG; Blazar BR; Wagner J; Diamond DJ; Verneris MR; Bryceson YT; Weisdorf DJ; Miller JS
Leukemia; 2016 Feb; 30(2):456-63. PubMed ID: 26416461
[TBL] [Abstract][Full Text] [Related]
24. CMV Triplex Vaccine to Enhance Adaptive NK and T-cell Reconstitution After Autologous Hematopoietic Cell Transplantation.
Rashidi A; La Rosa C; Curtsinger J; Cao Q; Zhou Q; Lingaraju CR; Weisdorf DJ; Cichocki F; Miller JS; Diamond DJ
Transplant Cell Ther; 2022 Jun; 28(6):343.e1-343.e4. PubMed ID: 35272066
[TBL] [Abstract][Full Text] [Related]
25. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function.
Foley B; Cooley S; Verneris MR; Pitt M; Curtsinger J; Luo X; Lopez-Vergès S; Lanier LL; Weisdorf D; Miller JS
Blood; 2012 Mar; 119(11):2665-74. PubMed ID: 22180440
[TBL] [Abstract][Full Text] [Related]
26. Emergence of human CMV-induced NKG2C+ NK cells is associated with CD8+ T-cell recovery after allogeneic HCT.
van der Ploeg K; Sottile R; Kontopoulos T; Shaffer BC; Papanicolaou GA; Maloy MA; Cho C; Robinson KS; Perales MA; Le Luduec JB; Hsu KC
Blood Adv; 2023 Oct; 7(19):5784-5798. PubMed ID: 37196646
[TBL] [Abstract][Full Text] [Related]
27. Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.
Kheav VD; Busson M; Scieux C; Peffault de Latour R; Maki G; Haas P; Mazeron MC; Carmagnat M; Masson E; Xhaard A; Robin M; Ribaud P; Dulphy N; Loiseau P; Charron D; Socié G; Toubert A; Moins-Teisserenc H
Haematologica; 2014 Dec; 99(12):1860-7. PubMed ID: 25085354
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
[TBL] [Abstract][Full Text] [Related]
29. The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation.
Zuo W; Yu XX; Liu XF; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Zhao XS; Huang XJ; Zhao XY
Front Immunol; 2022; 13():814334. PubMed ID: 35572602
[TBL] [Abstract][Full Text] [Related]
30. Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis.
Yang L; Tan Y; Shi J; Zhao Y; Yu J; Hu Y; Lai X; Yang Y; Huang H; Luo Y
Bone Marrow Transplant; 2021 Mar; 56(3):664-672. PubMed ID: 33077902
[TBL] [Abstract][Full Text] [Related]
31. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
[TBL] [Abstract][Full Text] [Related]
32. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
33. Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation.
Zhao XY; Luo XY; Yu XX; Zhao XS; Han TT; Chang YJ; Huo MR; Xu LP; Zhang XH; Liu KY; Li D; Jiang ZF; Huang XJ
Br J Haematol; 2017 Jun; 177(5):766-781. PubMed ID: 28466469
[TBL] [Abstract][Full Text] [Related]
34. Impact of extended infusional mesna prophylaxis on the incidence of BK viruria and hemorrhagic cystitis following post-transplantation cyclophosphamide and CTLA4Ig-based haploidentical transplantation.
Jaiswal SR; Singhal P; Thatai A; Bhagwati G; Aiyer HM; Chakrabarti A; Chakrabarti S
Ann Hematol; 2020 Apr; 99(4):839-845. PubMed ID: 32025839
[TBL] [Abstract][Full Text] [Related]
35. Late Development of FcεRγ
Muccio L; Falco M; Bertaina A; Locatelli F; Frassoni F; Sivori S; Moretta L; Moretta A; Della Chiesa M
Front Immunol; 2018; 9():1050. PubMed ID: 29868012
[TBL] [Abstract][Full Text] [Related]
36. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation.
Vago L; Forno B; Sormani MP; Crocchiolo R; Zino E; Di Terlizzi S; Lupo Stanghellini MT; Mazzi B; Perna SK; Bondanza A; Middleton D; Palini A; Bernardi M; Bacchetta R; Peccatori J; Rossini S; Roncarolo MG; Bordignon C; Bonini C; Ciceri F; Fleischhauer K
Blood; 2008 Oct; 112(8):3488-99. PubMed ID: 18645039
[TBL] [Abstract][Full Text] [Related]
37. Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation.
Baumeister SHC; Rambaldi B; Shapiro RM; Romee R
Front Immunol; 2020; 11():191. PubMed ID: 32117310
[TBL] [Abstract][Full Text] [Related]
38. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
39. Effect of mTOR Inhibition with Sirolimus on Natural Killer Cell Reconstitution in Allogeneic Stem Cell Transplantation.
Haroun-Izquierdo A; Lanuza PM; Pfefferle A; Netskar H; Ask EH; Törlén J; Björklund A; Sohlberg E; Malmberg KJ
Transplant Cell Ther; 2023 Jun; 29(6):376.e1-376.e11. PubMed ID: 36966873
[TBL] [Abstract][Full Text] [Related]
40. Single Cord Blood Transplantation Versus Unmanipulated Haploidentical Transplantation for Adults with Acute Myeloid Leukemia in Complete Remission.
Konuma T; Kanda J; Yamasaki S; Harada K; Shimomura Y; Terakura S; Mizuno S; Uchida N; Tanaka M; Doki N; Ozawa Y; Nakamae H; Sawa M; Matsuoka KI; Morishige S; Maruyama Y; Ikegame K; Kimura T; Kanda Y; Ichinohe T; Atsuta Y; Yanada M
Transplant Cell Ther; 2021 Apr; 27(4):334.e1-334.e11. PubMed ID: 33836881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
